Abbott India Ltd

His tenure will be for a period of five years, effective from 14 June 2025, to 13 June 2030. The appointment is expected to provide continued strategic leadership and drive growth initiatives for the company in the coming years. Abbott India is one of the leading multinational pharmaceutical companies in India and sells its products through independent distributors primarily within India. Abbott India's standalone net profit climbed 15.79% to Rs 415.27 crore on 7.62% increase in revenue from operations to Rs 1,757.15 crore in Q2 FY26 over Q2 FY25. Shares of Abbott India shed 0.63% to currently trade at Rs 29,536.05 on the BSE. Powered by Capital Market - Live

Abbott India has received approval from the Central Government under Section 196 of the Companies Act, 2013 for the appointment of Kartik Rajendran (DIN: 09527717) as the Managing Director of the Company, for a period of 5 (five) years, with effect from 14 June 2025 to 13 June 2030.Powered by Capital Market - Live

Net profit of Abbott India rose 15.80% to Rs 415.27 crore in the quarter ended September 2025 as against Rs 358.61 crore during the previous quarter ended September 2024. Sales rose 7.62% to Rs 1757.15 crore in the quarter ended September 2025 as against Rs 1632.67 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales1757.151632.67 8 OPM %28.5826.89 - PBDT564.57496.94 14 PBT545.93479.43 14 NP415.27358.61 16 Powered by Capital Market - Live

Profit before tax (PBT) stood at Rs 545.93 crore in Q2 FY26, up 13.87% year on year (YoY). Total expenses increased 5.55% to Rs 1,281.17 crore in Q2 FY26 as against Rs 1,213.72 crore posted in same quarter last year. The cost of materials consumed stood at Rs 162.59 crore (down 5.50% YoY), employee benefit expense was at Rs 158.98 crore (up 7.85% YoY) and finance cost was at Rs 7.55 crore (up 202% YoY) during the period under review. Abbott India is one of the leading multinational pharmaceutical companies in India and sells its products through independent distributors primarily within India. Shares of Abbott India rose 0.77% to settle at Rs 29,593.20 on the BSE. Powered by Capital Market - Live

Abbott India will hold a meeting of the Board of Directors of the Company on 6 November 2025.Powered by Capital Market - Live

Abbott India Ltd is up for a third straight session today. The stock is quoting at Rs 30500, up 1.79% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.5% on the day, quoting at 25018.1. The Sensex is at 81649.92, up 0.55%. Abbott India Ltd has slipped around 1.5% in last one month. Meanwhile, Nifty Pharma index of which Abbott India Ltd is a constituent, has slipped around 0.69% in last one month and is currently quoting at 21756.35, down 0.19% on the day. The volume in the stock stood at 2333 shares today, compared to the daily average of 10331 shares in last one month.The PE of the stock is 43.81 based on TTM earnings ending June 25.Powered by Capital Market - Live

Net profit of Abbott India rose 11.54% to Rs 365.86 crore in the quarter ended June 2025 as against Rs 328.01 crore during the previous quarter ended June 2024. Sales rose 11.60% to Rs 1738.35 crore in the quarter ended June 2025 as against Rs 1557.61 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales1738.351557.61 12 OPM %25.6325.10 - PBDT512.61455.59 13 PBT493.13437.22 13 NP365.86328.01 12 Powered by Capital Market - Live

Profit before tax (PBT) stood at Rs 493.13 crore in Q1 FY26, up 12.78% year on year (YoY). Total expenses increased 10.97% to Rs 1,318.06 crore in Q1 FY26 as against Rs 1,187.72 crore posted in same quarter last year. The cost of materials consumed stood at Rs 146.18 crore (down 0.06% YoY), employee benefit expense was at Rs 168.01 crore (up 4.31% YoY) and finance cost was at Rs 5.82 crore (up 111.63% YoY) during the period under review. Abbott India is one of the leading multinational pharmaceutical companies in India and sells its products through independent distributors primarily within India. Powered by Capital Market - Live

Abbott India will hold a meeting of the Board of Directors of the Company on 12 August 2025.Powered by Capital Market - Live

Abbott India Ltd is down for a fifth straight session today. The stock is quoting at Rs 34085, down 0.22% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is up around 0.01% on the day, quoting at 25523.95. The Sensex is at 83716.85, up 0.01%.Abbott India Ltd has added around 7.71% in last one month.Meanwhile, Nifty Pharma index of which Abbott India Ltd is a constituent, has increased around 1.15% in last one month and is currently quoting at 22165.9, up 0.15% on the day. The volume in the stock stood at 5270 shares today, compared to the daily average of 12264 shares in last one month.The PE of the stock is 51.39 based on TTM earnings ending March 25.Powered by Capital Market - Live